{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T23:32:13Z","timestamp":1778974333430,"version":"3.51.4"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1053\/j.seminhematol.2010.01.008","type":"journal-article","created":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T14:05:35Z","timestamp":1269957935000},"page":"148-155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Rituximab in High-Grade Lymphoma"],"prefix":"10.1053","volume":"47","author":[{"given":"Carsten","family":"Zwick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Murawski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Pfreundschuh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2010.01.008_bib1","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I","article-title":"Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma","volume":"38","author":"McKelvey","year":"1976","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib2","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib3","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM199705013361804","article-title":"High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma","volume":"336","author":"Gianni","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib4","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2000.18.16.3025","article-title":"Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol\u2014a Groupe d'Etude des Lymphomes de l'Adulte study","volume":"18","author":"Haioun","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib5","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJM199504203321601","article-title":"Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma","volume":"332","author":"Verdonck","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib6","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.1998.16.8.2796","article-title":"VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group","volume":"16","author":"Santini","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jnci\/93.1.22","article-title":"Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study","volume":"93","author":"Kluin-Nelemans","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib8","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1200\/JCO.2002.07.075","article-title":"Randomized study to evaluate the use of high-dose therapy as part of primary treatment for \u201caggressive\u201d lymphoma","volume":"20","author":"Kaiser","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib9","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2002.02.125","article-title":"Shortened first-line high-dose chemotherapy for patients with poor- prognosis aggressive lymphoma","volume":"20","author":"Gisselbrecht","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib10","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1200\/JCO.2003.01.117","article-title":"Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial","volume":"21","author":"Martelli","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib11","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa031770","article-title":"Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support","volume":"350","author":"Milpied","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib12","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/annonc\/mdl153","article-title":"Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL)","volume":"17","author":"Betticher","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib13","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/annonc\/mdi399","article-title":"Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG","volume":"16","author":"Olivieri","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib14","first-page":"793","article-title":"High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an \u201cIntergruppo Italiano Linfomi\u201d randomized trial","volume":"90","author":"Vitolo","year":"2005","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib15","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib16","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib18","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","article-title":"Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte","volume":"23","author":"Feugier","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib19","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab compared with CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the Mabthera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib20","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia","volume":"23","author":"Sehn","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib21","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood-2002-02-0469","article-title":"In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas","volume":"101","author":"Manches","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib22","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/sj.leu.2402559","article-title":"CD20-induced B cell death can bypass mitochondria and caspase activation","volume":"16","author":"Van der Kolk","year":"2002","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib23","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1365-3083.2000.00745.x","article-title":"Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms","volume":"51","author":"Harjunpaa","year":"2000","journal-title":"Scand J Immunol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib24","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/0008-5472.CAN-03-2862","article-title":"Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship","volume":"64","author":"Dall'Ozzo","year":"2004","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib25","first-page":"176","article-title":"The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes","volume":"91","author":"Golay","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib26","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptordependent mechanisms during anti-CD20 antibody immunotherapy","volume":"199","author":"Uchida","year":"2004","journal-title":"J Exp Med"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib27","first-page":"404","volume":"22","author":"Schmitz","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib28","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib30","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.8506","article-title":"A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin\u2018s lymphoma [abstract 8506]","volume":"27","author":"Cunningham","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib31","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib32","doi-asserted-by":"crossref","first-page":"430s","DOI":"10.1200\/jco.2006.24.18_suppl.7537","article-title":"Serum levels and pharmacokinetics of rituximab in bi-weekly R-CHOP in elderly patients with DLBCL treated in the RICOVER-60 trial [abstract]","volume":"24","author":"Reiser","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib33","doi-asserted-by":"crossref","first-page":"774a","DOI":"10.1182\/blood.V108.11.2738.2738","article-title":"Dose-dense rituximab in combination with bi-weekly CHOP-14 for elderly patients with diffuse large B-cell lymphoma: results of phase I\/II and pharmacokinetic study of the German High-grade Non-Hodgkin Lymphoma Study Group","volume":"108","author":"Poeschel","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib34","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib35","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.1998.16.10.3264","article-title":"Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial","volume":"16","author":"Guglielmi","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib36","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood.V60.3.693.693","article-title":"IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy","volume":"60","author":"Cabanillas","year":"1982","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/hon.2900100203","article-title":"Failure of IMVP-16 as second-line treatment for relapsed or refractory high grade non-Hodgkin's lymphoma","volume":"10","author":"De Lord","year":"1992","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","article-title":"Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)","volume":"71","author":"Velasquez","year":"1988","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib39","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3109\/10428199909058458","article-title":"Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma","volume":"33","author":"Soussain","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib40","first-page":"2766","article-title":"ESHAP chemotherapy for relapsed\/refractory non-Hodgkin's lymphoma","volume":"12","author":"Sweetenham","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib41","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","article-title":"ESHAP\u2014an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study","volume":"12","author":"Velasquez","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib42","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1200\/JCO.1995.13.7.1734","article-title":"Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP","volume":"13","author":"Rodriguez","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib43","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1200\/JCO.1993.11.8.1573","article-title":"EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma","volume":"11","author":"Wilson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib44","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood.V76.7.1293.1293","article-title":"CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma","volume":"76","author":"Chao","year":"1990","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib45","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2141.2001.02955.x","article-title":"Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma","volume":"114","author":"Cortelazzo","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib46","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/10428190600880084","article-title":"Dexa-BEAM as salvage therapy in patients with primary refractory aggressive non-Hodgkin lymphoma","volume":"48","author":"Atta","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib47","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/10428199909058430","article-title":"Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma","volume":"33","author":"Reiser","year":"1999","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib48","doi-asserted-by":"crossref","first-page":"161a","DOI":"10.1182\/blood.V108.11.532.532","article-title":"Phase II trial of dose-dense R-CHOP followed by risk-adapted consolidation with either ICE or ICE and ASCT, based upon the results of biopsy-confirmed abnormal interim restaging PET scan improves outcome of patients with advanced stage DLBCL [abstract]","volume":"108","author":"Moskowitz","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib49","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma","volume":"103","author":"Kewalramani","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib50","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/07357900600814490","article-title":"Dexamethasone, high-dose cytarabine and cisplatin in combination wirh rituximab as salvage treatment patients with relapsed or refractory aggressive non-Hodgkin\u2018s lymphoma","volume":"24","author":"Mey","year":"2006","journal-title":"Cancer Invest"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib51","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2007-08-108415","article-title":"Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed\/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial","volume":"111","author":"Vellenga","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib52","doi-asserted-by":"crossref","first-page":"436s","DOI":"10.1200\/jco.2009.27.15_suppl.8509","article-title":"R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma followed by autologous stem cell transplantation [abstract]","volume":"27","author":"Gisselbrecht","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib53","first-page":"3714","article-title":"Outcome of elderly patients with DLBCL failing R-CHOP. The role of rituximab and high dose therapy in second line treatment. A retrospective analysis from the RICOVER 60 trial. [abstract]","volume":"22","author":"Glass","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib54","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.3324\/haematol.13440","article-title":"R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL\/TAMO study","volume":"93","author":"Martin","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib55","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1093\/annonc\/mdm133","article-title":"Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy","volume":"18","author":"El Gnaoui","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib56","first-page":"836","article-title":"Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2018s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study [abstract]","author":"Van Oers","year":"2008","journal-title":"Am Soc Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib57","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib58","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event free survival and response duration compared with the standard weekly \u00d7 4 schedule","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.008_bib59","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin\u2018s lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:20:27Z","timestamp":1758522027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196310000090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0037196310000090"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.008","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab in High-Grade Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}